Rhythm Pharma Q2 FY26 net loss widens to $50.4 million; revenue rises 47% to $71.3 million

Reuters2026/08/04 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhythm Pharmaceuticals posted Q2 net product revenue of $71.3 million, up 47% from the year-ago quarter.
Net loss attributable to common stockholders widened to $50.4 million, or $0.73 per share, from $48.0 million, or $0.75 per share.
R&D expenses edged up to $43.4 million; SG&A expenses climbed to $67.4 million.
U.S. IMCIVREE launch in acquired hypothalamic obesity logged more than 400 patient start forms from about 300 prescribers since March 19 FDA approval.
Rhythm guided for 2026 non-GAAP operating expenses of $363 million-$397 million, excluding stock-based compensation and fixed in-licensing consideration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040701PRIMZONEFULLFEED9803149) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhythm Pharma Q2 FY26 net loss widens to $50.4 million; revenue rises 47% to $71.3 million

You may also like

Crypto prices